Review
Oncology
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen, Yu-Kang Tu, Jen-Yu Hung, Chih-Jen Yang, Inn-Wen Chong
Summary: Anaplastic lymphoma kinase inhibitors have shown excellent efficacy in treating non-small cell lung cancer patients, with lorlatinib and low-dose alectinib performing well in first-line treatment. Different agents have varying advantages in terms of outcomes, highlighting the need for further large-scale phase III clinical trials to confirm conclusions.
Review
Medicine, General & Internal
L. B. Cameron, N. Hitchen, E. Chandran, T. Morris, R. Manser, B. J. Solomon, V Jordan
Summary: This study evaluated the safety and efficacy of ALK inhibitors as monotherapy for advanced ALK-rearranged NSCLC. The results showed that ALK inhibitors are effective in improving progression-free survival, overall survival, and overall response rate, with minimal adverse events compared to chemotherapy. Next-generation ALK inhibitors are more effective and safe than first-generation ALK inhibitors. However, further research is needed to compare different next-generation ALK inhibitors.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Review
Oncology
Delphine Antoni, Helene Burckel, Georges Noel
Summary: The use of tyrosine kinase inhibitors has significantly improved outcomes for ALK-rearranged non-small cell lung cancer patients, and combining them with radiotherapy may increase effectiveness or overcome resistance. The identification of genetic alterations, such as ALK rearrangements in NSCLC patients, has led to a transformation in targeted therapies. The combination of ALK inhibitors and radiotherapy shows potential for improving treatment outcomes, although further research is needed to determine safety and efficacy.
Article
Immunology
Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, Chrystel Flores, Peter Brossart
Summary: This study investigates the immunosuppressive effects of two different ALK inhibitors on dendritic cells. The results show that crizotinib significantly suppresses the activation, migration, and cytokine production of dendritic cells, while alectinib has lesser immunosuppressive effects.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Li Wang, Wen Wang
Summary: ALK-TKIs have shown excellent clinical efficacy in treating ALK-positive NSCLC as first-line therapy, but resistance and adverse effects remain challenges. Proper management of these adverse effects is crucial in improving patient quality of life.
Review
Economics
Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous, William W. L. Wong
Summary: This article reviews the economic evidence of ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC) and finds that they can be considered a cost-effective treatment option. However, there is a lack of published studies and limited country perspectives, highlighting the need for more real-world data to conduct comparative cost-effectiveness analyses.
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Nick Pavlakis
Summary: The management of advanced lung cancer has been transformed by the identification of targetable oncogenic driver alterations, including ALK gene rearrangements. ALK tyrosine kinase inhibitors have become the first-line treatment options for advanced ALK rearranged NSCLC. However, drug resistance remains a challenge, and the role of anti-angiogenic therapy in ALK rearranged NSCLC needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Ines Mota, Enrico Patrucco, Cristina Mastini, Navin R. Mahadevan, Tran C. Thai, Elisa Bergaggio, Taek-Chin Cheong, Giulia Leonardi, Elif Karaca-Atabay, Marco Campisi, Teresa Poggio, Matteo Menotti, Chiara Ambrogio, Dario L. Longo, Susan Klaeger, Hasmik Keshishian, Zsofia M. Sztupinszki, Zoltan Szallasi, Derin B. Keskin, Jonathan S. Duke-Cohan, Bruce Reinhold, Steven A. Carr, Catherine J. Wu, Kelly D. Moynihan, Darrell J. Irvine, David A. Barbie, Ellis L. Reinherz, Claudia Voena, Mark M. Awad, Rafael B. Blasco, Roberto Chiarle
Summary: Mota et al. demonstrate that immunogenic ALK peptides can enhance the response to immune checkpoint blockade in ALK-rearranged NSCLC mouse models. They also identify immunogenic human ALK peptides for future translational research.
Review
Medicine, General & Internal
Kuan-Li Wu, Hsiao-Ling Chen, Ying-Ming Tsai, Tai-Huang Lee, Hsiu-Mei Chang, Yu-Chen Tsai, Cheng-Hao Chuang, Yong-Chieh Chang, Yu-Kang Tu, Chih-Jen Yang, Jen-Yu Hung, Inn-Wen Chong
Summary: This study compared newer generation ALKIs for treatment efficacy in Asian groups using network meta-analysis. Results showed that ensartinib may currently be the most effective first-line treatment for Asian patients with ALK-positive NSCLC. Additionally, low-dose alectinib exhibited efficacy similar to a higher dose regimen in Asian populations.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Kentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, Yoshihiro Hattori, Kazumi Nishino, Haruki Kobayashi, Yuko Oya, Toshihide Yokoyama, Takashi Seto, Koichi Azuma, Tomoya Fukui, Toshiyuki Kozuki, Atsushi Nakamura, Kentaro Tanaka, Katsuya Hirano, Takashi Yokoi, Haruko Daga, Shinya Sakata, Daichi Fujimoto, Masahide Mori, Ken Maeno, Takuya Aoki, Atsuhisa Tamura, Satoru Miura, Satoshi Watanabe, Hiroaki Akamatsu, Osamu Hataji, Kensuke Suzuki, Shigeto Hontsu, Koji Azuma, Akihiro Bessho, Akihito Kubo, Motoyasu Okuno, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Summary: The study revealed that in the sequential therapy of ALK-rearranged non-small cell lung cancer patients with CRZ and ALEC, the combined time-to-treatment failure in the CRZ group was significantly longer than the ALEC group, but there was no significant difference in overall survival between the two groups.
EUROPEAN JOURNAL OF CANCER
(2021)
Editorial Material
Oncology
Shelley Kuang, Natasha B. Leighl
Summary: The study in NEJM examined whether lorlatinib should be the standard first-line treatment for advanced ALK-rearranged lung cancer.
Article
Oncology
Marianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, Marianna Garonzi, Genny Buson, Claudio Forcato, Nicolo Manaresi, Agathe Aberlenc, Laura Mezquita, Yann Lecluse, Pernelle Lavaud, Charles Naltet, David Planchard, Benjamin Besse, Francoise Farace
Summary: Gatekeeper mutations are only identified in 50% of cases at resistance to ALK-TKIs. Circulating tumor cells (CTCs) are useful tools in identifying additional resistance mechanisms and can be sequenced at the single-cell level. Comprehensive analysis of CTCs reveals wide copy number alteration (CNA) heterogeneity and high chromosomal instability (CIN) at resistance to ALK-TKIs, providing valuable insights for precision medicine and overcoming resistance to ALK-targeted therapies.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Xiya Ma, Shaoxing Yang, Kun Zhang, Jing Xu, Panpan Lv, Hongjun Gao, Haifeng Qin, Hong Wang, Xiaoqing Liu
Summary: The study showed that using next-generation ALK-TKIs after crizotinib failure can significantly prolong survival in patients, with direct sequencing of lorlatinib showing a greater advantage. Similarly, lorlatinib demonstrated prolonged survival in patients who failed first- and second-generation ALK-TKIs treatment.
Article
Oncology
Takafumi Fukui, Motoko Tachihara, Tatsuya Nagano, Kazuyuki Kobayashi
Summary: Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) has made significant progress in recent years with the development of multiple tyrosine kinase inhibitors (TKIs) targeting ALK. Clinical trials of novel ALK-TKIs, angiogenesis inhibitors, immune checkpoint inhibitors, and chemotherapy are ongoing, and tissue and liquid biopsy are being explored as methods to investigate resistance mechanisms. This manuscript aims to provide information on these recent clinical trials and propose a treatment algorithm for ALK-rearranged advanced NSCLC.
Review
Oncology
Serena Ceddia, Giovanni Codacci-Pisanelli
Summary: Brain metastases are common in patients with ALK-translocated non-small cell lung cancer and are typically treated with radiotherapy. However, this can lead to severe late toxic side effects, prompting the use of ALK inhibitors such as crizotinib, alectinib, and brigatinib which have shown excellent activity against brain metastases. Starting treatment with specific inhibitors in asymptomatic patients and using radiotherapy when needed provides the best quality of life for patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Genetics & Heredity
Shuifang Lei, Lixi Li, Xiaoqin Yang, Qiming Yin, Tian Xu, Wenjie Zhou, Wanjian Gu, Fei Ma, Rongxi Yang
Summary: The study showed a significant association between breast cancer and blood-based RAPSN methylation influenced by age and HER2 status in the Chinese population.
JOURNAL OF HUMAN GENETICS
(2021)
Article
Oncology
Shaoyan Lin, Hongnan Mo, Yiqun Li, Xiuwen Guan, Yimeng Chen, Zijing Wang, Peng Yuan, Jiayu Wang, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Shanshan Chen, Pin Zhang, Qing Li, Fei Ma, Binghe Xu
Summary: This study conducted analyses on BCLM patients in the Han population and found that HR-/HER2+ and HR+/HER2+ subtypes, as well as patients with de novo stage IV breast cancer, had a higher risk of liver metastases, while patients with lung metastases had a lower risk. The median overall survival of BCLM patients was 31.4 months, with patients of HR+/HER2- subtype having the longest survival time of 38.2 months.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Fengzhu Guo, Zongbi Yi, Wenna Wang, Yiqun Han, Pei Yu, Su Zhang, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Jinhu Fan, Youlin Qiao, Jiayu Wang, Binghe Xu
Summary: The study analyzed the use of anthracycline-based chemotherapy in breast cancer patients in China, revealing that ABC remains a cornerstone in breast cancer treatment, particularly in neo and adjuvant therapy.
Article
Oncology
Ying Fan, Tao Sun, Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Zhongsheng Tong, Shusen Wang, Yang Luo, Yuee Teng, Xiaojia Wang, Shu Wang, Qiang Liu, Jifeng Feng, Kunwei Shen, Yanqiu Song, Jiayu Wang, Fei Ma, Qing Li, Pin Zhang, Binghe Xu
Summary: The study compared the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer. Patients receiving everolimus plus letrozole had a significantly longer median progression-free survival compared with those receiving letrozole alone, indicating the effectiveness of everolimus even after disease progression with the same endocrine agent.
Article
Oncology
Bo Lan, Dan Lv, Xiaoying Sun, Min Yang, Li Zhang, Fei Ma
Summary: This study found that variations in IL-10, IFNGR1, and BDNF genes are associated with anxiety and depression symptoms in Chinese breast cancer patients. This can help identify patients at high risk for psychological problems during chemotherapy and improve personalized management and treatment.
CLINICAL BREAST CANCER
(2022)
Article
Otorhinolaryngology
Di Zhang, Lixi Li, Tingyu Wen, Fei Ma
Summary: This study aimed to explore the clinical characteristics, prognostic factors, and value of adjuvant therapy for major salivary duct carcinoma (SDC). The study found that age, tumor size, and lymph node involvement were independent prognostic factors, and adjuvant radiotherapy could improve survival rates for patients with tumors larger than 4 cm.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2023)
Article
Oncology
Dan Lv, Bo Lan, Li Zhang, Xiaoying Sun, Min Yang, Fei Ma
Summary: This study found an association between depression status and chemotherapy-induced myelosuppression in Chinese breast cancer patients receiving adjuvant chemotherapy, but no association with other adverse events.
Article
Oncology
Di Zhang, Lixi Li, Fei Ma
Summary: This study aimed to evaluate the impact of postoperative radiation therapy (RT) on survival outcome in patients with adenoid cystic carcinoma of the breast (ACCB). The study found that postoperative RT significantly improved overall survival in the high-risk subgroup but had no significant effect in the low-risk subgroup.
Editorial Material
Oncology
Haili Qian
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Oncology
Hongmei Zeng, Siqi Wu, Fei Ma, John S. Ji, Lingeng Lu, Xianhui Ran, Jin Shi, Daojuan Li, Lan An, Rongshou Zheng, Siwei Zhang, Wanqing Chen, Wenqiang Wei, Yutong He, Jie He
Summary: The stage at diagnosis and molecular subtypes are important factors for breast cancer treatment and prognosis. This study aimed to examine the disparities and factors associated with the stage at diagnosis among molecular subtypes in Chinese breast cancer patients. The findings showed that China had a higher proportion of non-early-stage breast cancer compared to the United States, highlighting the need for improved early diagnosis and health equity in China.
Article
Oncology
Jiaxuan Liu, Maiyue He, Kaiping Ou, Xin Wang, Yipeng Wang, Liqiang Qi, Yue Chai, Mingxia Jiang, Fei Ma, Yang Luo, Peng Yuan, Pin Zhang, Binghe Xu, Qiao Li
Summary: This prospective cohort study investigated the efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin (Apa+ddTCb) compared to dose-dense paclitaxel plus carboplatin regimens alone (ddTCb) in neoadjuvant therapy for locally advanced triple-negative breast cancer (TNBC). The results showed that the Apa+ddTCb regimen significantly improved pathological complete response (pCR) rate and breast-conserving surgery (BCS) rate compared to the ddTCb regimen, but had a higher incidence of adverse events. Immunohistochemical analysis also demonstrated decreased expression levels of VEGF, EGFR, p-VEGFR2, and CK17 in the Apa+ddTCb group. Overall, the Apa+ddTCb regimen may be a promising strategy for neoadjuvant therapy in locally advanced TNBC.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Yi-Qun Li, Fang-Zhou Sun, Chun-Xiao Li, Hong-Nan Mo, Yan-Tong Zhou, Dan Lv, Jing-Tong Zhai, Hai-Li Qian, Fei Ma
Summary: The down-regulation of RARRES2 is specifically associated with brain metastasis (BrM) of triple negative breast cancer (TNBC) and promotes BrM through lipid metabolic reprogramming. Mechanistically, reduced expression of RARRES2 results in altered levels of glycerophospholipid and triacylglycerols by regulating the PTEN-mTOR-SREBP1 signaling pathway. This study uncovers the essential role of RARRES2 in linking lipid metabolic reprogramming and the development of BrM, providing potential biomarkers or therapeutic targets for BCBrM.
MILITARY MEDICAL RESEARCH
(2023)
Letter
Biochemistry & Molecular Biology
Xiuwen Guan, Fei Ma, Qiao Li, Shanshan Chen, Ying Fan, Jiayu Wang, Yang Luo, Pin Zhang, Qing Li, Binghe Xu
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Oncology
Mingxia Jiang, Bin Shao, Donggui Wan, Jiaxuan Liu, Maiyue He, Yue Chai, Die Sang, Jiayu Wang, Fei Ma, Ying Fan, Peng Yuan, Binghe Xu, Qiao Li
Summary: This study retrospectively analyzed the efficacy and safety of eribulin combined with antiangiogenic drugs in the treatment of HER2-negative metastatic breast cancer. The results showed that this treatment regimen had significant clinical activity and an acceptable safety profile in HER2-negative MBC patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Zongbi Yi, Fei Ma, Guohua Rong, Binliang Liu, Yanfang Guan, Jin Li, Xiaoying Sun, Wenna Wang, Xiuwen Guan, Hongnan Mo, Jiani Wang, Haili Qian, Binghe Xu
Summary: The study discovered that mTBI in ctDNA is a potential biomarker for therapeutic response and prognosis in metastatic breast cancer patients. Patients with high mTBI values had shorter overall survival, while those with decreased mTBI values after treatment had longer progression-free and overall survival.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)